CEL-SCI Presents New Data from Multikine Phase 3 Clinical Trial
CEL-SCI's revolutionary advances are impressive; their data shows that overall survival increased by almost 4 years, and some tumors even ...
The NY Journals pride themselves on assembling a proficient and dedicated team comprising seasoned journalists and editors. This collective commitment drives us to provide our esteemed readership with nothing short of the most comprehensive, accurate, and captivating news coverage available.
Transcending the bounds of New York City to encompass a broader scope, we ensure that our audience remains well-informed and engaged with the latest developments, both locally and beyond.
NEWS
- Business
- Technology
- Entertainment
- Sports
- Lifestyle
- Health
- Politics
- Real Estate
© 2025 The New York Journals. All Rights Reserved.